Rates of lobar atrophy in asymptomatic MAPT mutation carriers

Qin Chen, Bradley F. Boeve, Matthew Senjem, Nirubol Tosakulwong, Timothy G. Lesnick, Danielle Brushaber, Christina Dheel, J. Fields, Leah Forsberg, Ralitza Gavrilova, D. Gearhart, Jonathan Graff-Radford, Neill R. Graff-Radford, Clifford R. Jack, David T. Jones, David S. Knopman, Walter K. Kremers, M. Lapid, Rosa Rademakers, Jeremy SyrjanenAdam L. Boxer, H. Rosen, Zbigniew K. Wszolek, K. Kantarci

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: The aim of this study was to investigate the rates of lobar atrophy in the asymptomatic microtubule-associated protein tau (MAPT) mutation carriers. Methods: MAPT mutation carriers (n = 14; 10 asymptomatic, 4 converters from asymptomatic to symptomatic) and noncarriers (n = 13) underwent structural magnetic resonance imaging and were followed annually with a median of 9.2 years. Longitudinal changes in lobar atrophy were analyzed using the tensor-based morphometry with symmetric normalization algorithm. Results: The rate of temporal lobe atrophy in asymptomatic MAPT mutation carriers was faster than that in noncarriers. Although the greatest rate of atrophy was observed in the temporal lobe in converters, they also had increased atrophy rates in the frontal and parietal lobes compared to noncarriers. Discussion: Accelerated decline in temporal lobe volume occurs in asymptomatic MAPT mutation carriers followed by the frontal and parietal lobe in those who have become symptomatic. The findings have implications for monitoring the progression of neurodegeneration during clinical trials in asymptomatic MAPT mutation carriers.

Original languageEnglish (US)
Pages (from-to)338-346
Number of pages9
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Volume5
DOIs
StatePublished - Jan 1 2019

Fingerprint

Microtubule-Associated Proteins
Atrophy
Temporal Lobe
Mutation
Parietal Lobe
Frontal Lobe
Magnetic Resonance Imaging
Clinical Trials

Keywords

  • Asymptomatic
  • Frontotemporal dementia
  • Longitudinal
  • Magnetic resonance image
  • MAPT

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Rates of lobar atrophy in asymptomatic MAPT mutation carriers. / Chen, Qin; Boeve, Bradley F.; Senjem, Matthew; Tosakulwong, Nirubol; Lesnick, Timothy G.; Brushaber, Danielle; Dheel, Christina; Fields, J.; Forsberg, Leah; Gavrilova, Ralitza; Gearhart, D.; Graff-Radford, Jonathan; Graff-Radford, Neill R.; Jack, Clifford R.; Jones, David T.; Knopman, David S.; Kremers, Walter K.; Lapid, M.; Rademakers, Rosa; Syrjanen, Jeremy; Boxer, Adam L.; Rosen, H.; Wszolek, Zbigniew K.; Kantarci, K.

In: Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 5, 01.01.2019, p. 338-346.

Research output: Contribution to journalArticle

@article{584310d31a064ec0ac047dbdb02dc391,
title = "Rates of lobar atrophy in asymptomatic MAPT mutation carriers",
abstract = "Introduction: The aim of this study was to investigate the rates of lobar atrophy in the asymptomatic microtubule-associated protein tau (MAPT) mutation carriers. Methods: MAPT mutation carriers (n = 14; 10 asymptomatic, 4 converters from asymptomatic to symptomatic) and noncarriers (n = 13) underwent structural magnetic resonance imaging and were followed annually with a median of 9.2 years. Longitudinal changes in lobar atrophy were analyzed using the tensor-based morphometry with symmetric normalization algorithm. Results: The rate of temporal lobe atrophy in asymptomatic MAPT mutation carriers was faster than that in noncarriers. Although the greatest rate of atrophy was observed in the temporal lobe in converters, they also had increased atrophy rates in the frontal and parietal lobes compared to noncarriers. Discussion: Accelerated decline in temporal lobe volume occurs in asymptomatic MAPT mutation carriers followed by the frontal and parietal lobe in those who have become symptomatic. The findings have implications for monitoring the progression of neurodegeneration during clinical trials in asymptomatic MAPT mutation carriers.",
keywords = "Asymptomatic, Frontotemporal dementia, Longitudinal, Magnetic resonance image, MAPT",
author = "Qin Chen and Boeve, {Bradley F.} and Matthew Senjem and Nirubol Tosakulwong and Lesnick, {Timothy G.} and Danielle Brushaber and Christina Dheel and J. Fields and Leah Forsberg and Ralitza Gavrilova and D. Gearhart and Jonathan Graff-Radford and Graff-Radford, {Neill R.} and Jack, {Clifford R.} and Jones, {David T.} and Knopman, {David S.} and Kremers, {Walter K.} and M. Lapid and Rosa Rademakers and Jeremy Syrjanen and Boxer, {Adam L.} and H. Rosen and Wszolek, {Zbigniew K.} and K. Kantarci",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.trci.2019.05.010",
language = "English (US)",
volume = "5",
pages = "338--346",
journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",
issn = "2352-8737",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Rates of lobar atrophy in asymptomatic MAPT mutation carriers

AU - Chen, Qin

AU - Boeve, Bradley F.

AU - Senjem, Matthew

AU - Tosakulwong, Nirubol

AU - Lesnick, Timothy G.

AU - Brushaber, Danielle

AU - Dheel, Christina

AU - Fields, J.

AU - Forsberg, Leah

AU - Gavrilova, Ralitza

AU - Gearhart, D.

AU - Graff-Radford, Jonathan

AU - Graff-Radford, Neill R.

AU - Jack, Clifford R.

AU - Jones, David T.

AU - Knopman, David S.

AU - Kremers, Walter K.

AU - Lapid, M.

AU - Rademakers, Rosa

AU - Syrjanen, Jeremy

AU - Boxer, Adam L.

AU - Rosen, H.

AU - Wszolek, Zbigniew K.

AU - Kantarci, K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: The aim of this study was to investigate the rates of lobar atrophy in the asymptomatic microtubule-associated protein tau (MAPT) mutation carriers. Methods: MAPT mutation carriers (n = 14; 10 asymptomatic, 4 converters from asymptomatic to symptomatic) and noncarriers (n = 13) underwent structural magnetic resonance imaging and were followed annually with a median of 9.2 years. Longitudinal changes in lobar atrophy were analyzed using the tensor-based morphometry with symmetric normalization algorithm. Results: The rate of temporal lobe atrophy in asymptomatic MAPT mutation carriers was faster than that in noncarriers. Although the greatest rate of atrophy was observed in the temporal lobe in converters, they also had increased atrophy rates in the frontal and parietal lobes compared to noncarriers. Discussion: Accelerated decline in temporal lobe volume occurs in asymptomatic MAPT mutation carriers followed by the frontal and parietal lobe in those who have become symptomatic. The findings have implications for monitoring the progression of neurodegeneration during clinical trials in asymptomatic MAPT mutation carriers.

AB - Introduction: The aim of this study was to investigate the rates of lobar atrophy in the asymptomatic microtubule-associated protein tau (MAPT) mutation carriers. Methods: MAPT mutation carriers (n = 14; 10 asymptomatic, 4 converters from asymptomatic to symptomatic) and noncarriers (n = 13) underwent structural magnetic resonance imaging and were followed annually with a median of 9.2 years. Longitudinal changes in lobar atrophy were analyzed using the tensor-based morphometry with symmetric normalization algorithm. Results: The rate of temporal lobe atrophy in asymptomatic MAPT mutation carriers was faster than that in noncarriers. Although the greatest rate of atrophy was observed in the temporal lobe in converters, they also had increased atrophy rates in the frontal and parietal lobes compared to noncarriers. Discussion: Accelerated decline in temporal lobe volume occurs in asymptomatic MAPT mutation carriers followed by the frontal and parietal lobe in those who have become symptomatic. The findings have implications for monitoring the progression of neurodegeneration during clinical trials in asymptomatic MAPT mutation carriers.

KW - Asymptomatic

KW - Frontotemporal dementia

KW - Longitudinal

KW - Magnetic resonance image

KW - MAPT

UR - http://www.scopus.com/inward/record.url?scp=85069885589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069885589&partnerID=8YFLogxK

U2 - 10.1016/j.trci.2019.05.010

DO - 10.1016/j.trci.2019.05.010

M3 - Article

AN - SCOPUS:85069885589

VL - 5

SP - 338

EP - 346

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

SN - 2352-8737

ER -